{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:42Z","timestamp":1791908202614,"version":"4.3.4"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SCRIPS Foundation\/Burroughs Wellcome Fund. D.B.J.","award":["NCI R01CA227481"],"award-info":[{"award-number":["NCI R01CA227481"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of metastatic melanoma patients that fail multiple lines of systemic therapy remains a significant challenge. There is limited literature regarding combination of anti-PD-1 and temozolomide, or of other chemotherapy agents, in melanoma. Here, we present a series of 3 patients with metastatic melanoma and their responses to nivolumab and temozolomide combination therapy after progression on several local\/regional therapies, combination immune checkpoint inhibitors, and\/or targeted therapies. The novel combinatory strategy led to remarkable responses in all 3 patients shortly after initiating treatment with tumor remission and symptomatic improvement. The first patient has had ongoing response 15 months after initiating treatment, although he has since discontinued temozolomide due to intolerance. The remaining 2 patients show ongoing response after 4 months, with good tolerability. This case series suggests that nivolumab and temozolomide may be a promising option in the setting of advanced melanoma refractory to standard treatments, and warrants further investigation in larger series.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad184","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:23:50Z","timestamp":1687263830000},"page":"e839-e842","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-8108","authenticated-orcid":false,"given":"Rachel S","family":"Goodman","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Vanderbilt University School of Medicine , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeon","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Vanderbilt University School of Medicine , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Quintos","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Vanderbilt University School of Medicine , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"7","key":"2023090805124791700_CIT0001","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"2023090805124791700_CIT0002","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2023090805124791700_CIT0003","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","article-title":"Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients","volume":"30","author":"Vera Aguilera","year":"2020","journal-title":"Melanoma Res"},{"issue":"7","key":"2023090805124791700_CIT0004","doi-asserted-by":"crossref","first-page":"e1331807","DOI":"10.1080\/2162402X.2017.1331807","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"5","key":"2023090805124791700_CIT0005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2023090805124791700_CIT0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.lungcan.2018.08.019","article-title":"Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study","volume":"125","author":"Gadgeel","year":"2018","journal-title":"Lung Cancer"},{"issue":"22","key":"2023090805124791700_CIT0007","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2023090805124791700_CIT0008","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023090805124791700_CIT0009","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"issue":"21","key":"2023090805124791700_CIT0010","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.21037\/atm-21-5738","article-title":"Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e839\/51436928\/oyad184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e839\/51436928\/oyad184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:13:30Z","timestamp":1694150010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/9\/e839\/7203715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,6,20]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad184","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,6,20]]}}}